Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.63 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7980 | 1.00 | MIF (0.63) | MIFNOS2ADRA2CKDM4ELMNA | |
| SCHEMBL6583 | 1.00 | MIF (0.63) | MIFNOS2ADRA2CKDM4ELMNA | |
| SCHEMBL27902285 | 0.94 | MIF (0.57) | MIFNOS2ADRA2CKDM4ELMNA | |
| SCHEMBL23070416 | 0.94 | MIF (0.57) | MIFNOS2ADRA2CKDM4ELMNA | |
| SCHEMBL443529 | 0.88 | MIF (0.46) | MIFNOS2CYP3A4 | |
| SCHEMBL28671467 | 0.88 | MIF (0.50) | MIFCYP2C9PKMCYP2C19 | |
| SCHEMBL22279429 | 0.88 | MIF (0.50) | MIFCYP2C9PKMCYP2C19 | |
| SCHEMBL7192060 | 0.84 | MIF (0.45) | MIFNOS2KDM4ELMNAHIF1A | |
| SCHEMBL22265179 | 0.83 | MIF (0.46) | MIFADRA2CLMNAADRA2AALDH1A1 | |
| SCHEMBL22265178 | 0.83 | MIF (0.46) | MIFADRA2CLMNAADRA2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025131930-A1 | NON-AQUEOUS COATING COMPOSITION | ALLNEX NETHERLANDS B.V. (NL) | 2025-06-26 | — | — | WO | claimed |
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | claimed |
| US-20220380303-A1 | PROCESS FOR THE DISTILLATION OF ISOCYANATES | COVESTRO DEUTSCHLAND AG (DE) | 2022-12-01 | — | — | US | claimed |
| CN-113720925-A | Separation detection method of isocyanate derivative | 武汉武药科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-109725073-B | Separation and detection method of acetylcysteine enantiomer | 湖南华纳大药厂科技开发有限公司 | 2021-10-15 | — | — | CN | claimed |
| CN-111978448-B | Ureido-modified (S) -2-ethynylpyrrolidine and preparation method and application thereof | 北京大学 | 2021-04-13 | — | — | CN | claimed |
| CN-111978448-A | Ureido-modified (S) -2-ethynylpyrrolidine and preparation method and application thereof | 北京大学 | 2020-11-24 | — | — | CN | claimed |
| EP-1717223-B1 | Method for the purification of isocyanates | BASF SE (DE) | 2016-07-20 | — | — | EP | claimed |
| US-8088944-B2 | Method for the purification of isocyanates | BASF SE (DE) | 2012-01-03 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | claimed |
| EP-1487448-A4 | TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS | SEMPACH PTY LTD (AU) | 2007-04-25 | — | — | EP | claimed |
| US-20070015934-A1 | Method for the purification of isocyanates | BASF AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20050119350-A1 | Treatment of effect of chemicals with their ultradilute stereoisomers | SEMPACH PTY LTD ACN 078 746 522 (AU) | 2005-06-02 | — | — | US | claimed |
| EP-1487448-A1 | TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS | Sempach PTY Ltd (AU) | 2004-12-22 | — | — | EP | claimed |
| WO-2003072105-A1 | TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS | SEMPACH PTY LTD (AU) | 2003-09-04 | — | — | WO | claimed |
| EP-4739393-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | Merck Sharp & Dohme LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | disclosed |
| EP-0077983-A1 | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | MIF 3168/4885NOS2 1398/4885ADRA2C 854/4885 |
| US-11760750-B1 | Process for preparing levoketoconazole | KHK, KYAT3, PLK3 | MIF 2851/4885NOS2 3874/4885ADRA2C 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.